Paired Immunoglobulin-Like Receptor-B (PIRB) Regulates the Suppressive Function and M1/M2 Differentiation of MDSCs

S. Eisenstein,G. Ma,P. Pan,S. Chen,C. Divino
DOI: https://doi.org/10.1016/j.jss.2009.11.636
IF: 2.417
2010-01-01
Journal of Surgical Research
Abstract:Introduction: Myeloid derived suppressor cells (MDSCs), which constitute a major component of the leukocyte infiltrate in tumors, are a mixed population of immature myeloid cells that bear the characteristics of both M1 and M2 macrophages. The molecular mechanism that controls M1 and M2 switching is still unknown. Paired immunoglobulin-like receptors include PIRA and PIRB in mice and their counterpart in humans is leukocyte immunoglobulin-like receptor (LILR). PIRB KO mice exhibit hyper-responsiveness in a variety of cells, and, by elucidating the function of PIRB in MDSC differentiation, their role in tumor-induced immunity will become clearer. Objective: To study PIRB function in MDSCs using PIRB KO mice and to find a possible mechanism in which PIRB regulates MDSC differentiation into M1 and M2 macrophages. Results: 1. PIRB KO MDSCs derived from spleen exhibit 65.7% (MDSC:T cell=1:1) weaker suppressive activity and a 43.1% decrease in Treg induction, whereas those derived from bone marrow have 47.6% (MDSC:T cell=1:1) stronger suppressive function and a 32.5% increase in Treg induction in vitro, compared to controls. 2. PIRB KO bone marrow MDSCs significantly increase M2 related functional factors: arginase activity increases 90% and IL-10 production 40%, whereas splenic MDSCs significantly decrease arginase activity by 60% and IL-10 production by 26%. Meanwhile, PIRB KO splenic MDSCs significantly increase M1 related functional factors: iNOS activity increases by 72% and TNF-α production by 71%, whereas bone marrow MDSCs significantly decrease iNOS activity by 80% and TNF-α production by 58%. 3. PIRB KO MDSCs from bone marrow (54.6%) and spleen (36.7%) have reduced suppressive function, and Treg inducing abilities (35.6% and 38.6%, respectively) in vivo, which may be because of preferential M1 development. 4. Tumor growth is significantly delayed in the first 24 days after injection in PIRB KO mice. Conclusion: PIRB KO MDSCs show a shift from a M2 phenotype in bone marrow to a M1 phenotype in the spleen and exhibit decreased suppressive function and Treg induction. This may occur through STAT and TLR pathways causing phenotypical and functional changes in PIRB KO MDSCs. Blockade of PIRB signaling will favor M1 development, the promotion of an anti-tumor response, and prevent T-cell suppression.
What problem does this paper attempt to address?